Trial Review

Registering a new trial?

To achieve prospective registration, we recommend submitting your trial for registration at the same time as ethics submission.

The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been endorsed by the ANZCTR. Before participating in a study, talk to your health care provider and refer to this information for consumers
Trial details imported from ClinicalTrials.gov

For full trial details, please see the original record at https://clinicaltrials.gov/study/NCT03354663




Registration number
NCT03354663
Ethics application status
Date submitted
17/11/2017
Date registered
28/11/2017
Date last updated
11/10/2023

Titles & IDs
Public title
TactiSense IDE Trial of TactiCath SE for Paroxysmal Atrial Fibrillation
Scientific title
Multi-Center Acute Safety Trial of TactiCath™ Contact Force Ablation Catheter, Sensor Enabled™ (TactiCath SE) for the Treatment of Drug Refractory Recurrent Symptomatic Paroxysmal Atrial Fibrillation
Secondary ID [1] 0 0
SJM-CIP-10216
Universal Trial Number (UTN)
Trial acronym
TactiSense
Linked study record

Health condition
Health condition(s) or problem(s) studied:
Paroxysmal Atrial Fibrillation 0 0
Condition category
Condition code
Cardiovascular 0 0 0 0
Other cardiovascular diseases

Intervention/exposure
Study type
Interventional
Description of intervention(s) / exposure
Treatment: Devices - TactiCath SE

Experimental: TactiCath SE - Catheter ablation with the TactiCath SE ablation catheter to achieve pulmonary vein isolation.


Treatment: Devices: TactiCath SE
Ablation to achieve pulmonary vein isolation.
Intervention code [1] 0 0
Treatment: Devices
Comparator / control treatment
Control group

Outcomes
Primary outcome [1] 0 0
Rate of Serious Adverse Events
Timepoint [1] 0 0
30 days
Primary outcome [2] 0 0
Number of Participants With Procedural Success
Timepoint [2] 0 0
0 days

Eligibility
Key inclusion criteria
* Plans to undergo a catheter ablation procedure due to symptomatic PAF that is refractory or intolerant to at least one Class I or III antiarrhythmic drug
* Physician's note indicating recurrent self-terminating AF
* One electrocardiographically documented AF episode within 6 months prior to the index ablation procedure
* At least 18 years of age
* Able and willing to comply with all trial requirements
* Informed of the nature of the trial, agreed to its provisions and has provided written informed consent as approved by the Institutional Review Board/Ethics Committee (IRB/EC) of the respective clinical trial site.
Minimum age
18 Years
Maximum age
No limit
Sex
Both males and females
Can healthy volunteers participate?
No
Key exclusion criteria
* Persistent or long-standing persistent atrial fibrillation (AF)
* Four or more cardioversions in the past 12 months
* Active systemic infection
* Known presence of cardiac thrombus
* Implanted with implantable cardiac defibrillator (ICD)
* Arrhythmia due to reversible causes including thyroid disorders, acute alcohol intoxication, and other major surgical procedures in the preceding 3 months
* Myocardial infarction (MI), acute coronary syndrome, percutaneous coronary intervention (PCI), or valve or coronary bypass grafting surgery within preceding 3 months
* Left atrial diameter > 5.0 cm
* Left ventricular ejection fraction < 35%
* New York Heart Association (NYHA) class III or IV
* Previous left atrial surgical or catheter ablation procedure
* Left atrial surgical procedure or incision with resulting scar
* Previous tricuspid or mitral valve replacement or repair
* Heart disease in which corrective surgery is anticipated within 6 months
* Bleeding diathesis or suspected procoagulant state
* Contraindication to long term antithromboembolic therapy
* Presence of any condition that precludes appropriate vascular access
* Renal failure requiring dialysis
* Known sensitivity to contrast media (if needed during the procedure) that cannot be controlled with pre-medication
* Severe pulmonary disease (e.g., restrictive pulmonary disease, constrictive or chronic obstructive pulmonary disease) or any other disease or malfunction of the lungs or respiratory system that produces severe chronic symptoms
* Pregnant or nursing
* Presence of other anatomic or comorbid conditions that, in the investigator's opinion, could limit the patient's ability to participate in the clinical trial or to comply with follow up requirements, or impact the scientific soundness of the clinical trial results
* Patient is currently participating in another clinical trial or has participated in a clinical trial within 30 days prior to screening that may interfere with this clinical trial
* Patient is unlikely to survive the protocol follow up period of 12 months
* Body mass index > 40 kg/m2
* Vulnerable subject

Study design
Purpose of the study
Treatment
Allocation to intervention
NA
Procedure for enrolling a subject and allocating the treatment (allocation concealment procedures)
Methods used to generate the sequence in which subjects will be randomised (sequence generation)
Masking / blinding
Open (masking not used)
Who is / are masked / blinded?



Intervention assignment
Single group
Other design features
Phase
NA
Type of endpoint/s
Statistical methods / analysis

Recruitment
Recruitment status
Completed
Data analysis
Reason for early stopping/withdrawal
Other reasons
Date of first participant enrolment
Anticipated
Actual
11/12/2017
Date of last participant enrolment
Anticipated
Actual
Date of last data collection
Anticipated
Actual
30/10/2019
Sample size
Target
Accrual to date
Final
156
Recruitment in Australia
Recruitment state(s)
Recruitment hospital [1] 0 0
Ashford Hospital - Adelaide
Recruitment hospital [2] 0 0
Royal Adelaide Hospital - Adelaide
Recruitment hospital [3] 0 0
Royal Melbourne Hospital - City Campus - Melbourne
Recruitment postcode(s) [1] 0 0
5000 - Adelaide
Recruitment postcode(s) [2] 0 0
- Adelaide
Recruitment postcode(s) [3] 0 0
3050 - Melbourne
Recruitment outside Australia
Country [1] 0 0
United States of America
State/province [1] 0 0
Arkansas
Country [2] 0 0
United States of America
State/province [2] 0 0
California
Country [3] 0 0
United States of America
State/province [3] 0 0
Colorado
Country [4] 0 0
United States of America
State/province [4] 0 0
District of Columbia
Country [5] 0 0
United States of America
State/province [5] 0 0
Florida
Country [6] 0 0
United States of America
State/province [6] 0 0
Georgia
Country [7] 0 0
United States of America
State/province [7] 0 0
Kentucky
Country [8] 0 0
United States of America
State/province [8] 0 0
Minnesota
Country [9] 0 0
United States of America
State/province [9] 0 0
New York
Country [10] 0 0
United States of America
State/province [10] 0 0
Ohio
Country [11] 0 0
United States of America
State/province [11] 0 0
South Carolina
Country [12] 0 0
United States of America
State/province [12] 0 0
Texas
Country [13] 0 0
Germany
State/province [13] 0 0
Saxony
Country [14] 0 0
Germany
State/province [14] 0 0
Dresden
Country [15] 0 0
Italy
State/province [15] 0 0
Lombardy
Country [16] 0 0
Italy
State/province [16] 0 0
Milan

Funding & Sponsors
Primary sponsor type
Commercial sector/industry
Name
Abbott Medical Devices
Address
Country

Ethics approval
Ethics application status

Summary
Brief summary
Trial website
Trial related presentations / publications
Public notes

Contacts
Principal investigator
Name 0 0
Kristin Ruffner, PhD MBA
Address 0 0
Abbott
Country 0 0
Phone 0 0
Fax 0 0
Email 0 0
Contact person for public queries
Name 0 0
Address 0 0
Country 0 0
Phone 0 0
Fax 0 0
Email 0 0
Contact person for scientific queries

No information has been provided regarding IPD availability


What supporting documents are/will be available?




Results publications and other study-related documents

No documents have been uploaded by study researchers.

Results are available at https://clinicaltrials.gov/study/NCT03354663